Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Genmab
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Cellectar Biosciences, Inc.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
M.D. Anderson Cancer Center
Dizal Pharmaceuticals
Merck Sharp & Dohme LLC
Ohio State University Comprehensive Cancer Center
Alliance for Clinical Trials in Oncology
University of Wisconsin, Madison
H. Lee Moffitt Cancer Center and Research Institute
Massachusetts General Hospital
Swiss Cancer Institute
Miltenyi Biomedicine GmbH
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
University of Washington
Regeneron Pharmaceuticals
Barbara Ann Karmanos Cancer Institute
City of Hope Medical Center
Mayo Clinic
University of Rochester
University Hospital Southampton NHS Foundation Trust
City of Hope Medical Center
University of Chicago
Hutchmed
Samsung Medical Center
Ruijin Hospital
Shanghai Ming Ju Biotechnology Co., Ltd.
Genmab
Cothera Bioscience, Inc
Seoul National University Hospital
University of Southampton
Northwestern University
Nordic Lymphoma Group
Fudan University